ResearchMoz is the one stop online destination to find and buy market research reports and Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Wednesday, 2 December 2015

EpiCast Report: Hepatocellular Carcinoma - Epidemiology Forecast to 2024

Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver. HCC is classified by various staging systems such as the Barcelona Clinic Liver Cancer (BCLC) stage and Child Pugh stages. The major risk factors for HCC are hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and alcohol abuse. HCC is more common in men than women, averaging between two to four times as many cases in men as in women. This could be due to men being more likely to be infected with HBV and HCV, to consume more alcohol, to smoke cigarettes, or to have increased iron stores.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of HCC will increase from 103,308 cases in 2014 to 123,658 cases in 2024 at an Annual Growth Rate (AGR) of 1.97%. Japan had the highest number of diagnosed incident cases of HCC among the 7MM throughout the forecast period. In the 7MM in 2014 there were 38,359 diagnosed incident cases of BCLC stage A, 26,558 cases of BCLC stage B, 26,527 cases of BCLC stage C, and 11,865 cases of BCLC stage D. GlobalData epidemiologists estimated that the 7MM in 2014 had 150,488 five-year diagnosed prevalent cases of HCC, 10,835 diagnosed incident cases of HCC with HBV, and 62,140 diagnosed incident cases of HCC with HCV.

The overall increase in the incidence of HCC in the 7MM was mostly driven by population changes, as GlobalData epidemiologists observed very little historical changes in the incidence of HCC. During the forecast period, changes in alcohol use/abuse among men and women may impact the incidence of HCC in the US and UK. Furthermore, the high prevalence of HCV in Italy and Japan will continue to contribute to HCC incidence.

GlobalData’s epidemiological forecast for the diagnosed incident and the five-year diagnosed prevalent cases of HCC in the 7MM is supported by age- and sex-specific data for the incidence. The one- to five-year relative survival data, which were used for the five-year diagnosed prevalent cases forecast, are supported by country-specific, population-based studies that are representative of the national population in the respective markets.


The Hepatocellular Carcinoma (HCC) EpiCast Report provides an overview of the risk factors and global trends of HCC in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of HCC in these markets. The diagnosed incident cases of HCC are segmented by age (30–39 years, 40–49 years, 50–59 years, 60–69 years, and 70–79 years, =80 years), sex, BCLC stage at diagnosis, and comorbidity with HBV or HCV.
The HCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The HCC EpiCast series will allow you to -

Develop business strategies by understanding the trends shaping and driving the global HCC market.
Quantify patient populations in the global HCC market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HCC therapeutics in each of the markets covered.
Identify the percentage of HCC incident cases by stage at diagnosis and comorbidity with HBV or HCV.

For More Information Kindly Contact:
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948


Post a Comment